Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report ongoing study by
Infinium Global Research on the AI-based clinical trials solution provider market
provides an in-depth analysis of segments and sub-segments in the GCC as well as
regional AI-based clinical trials solution provider market. The study also
highlights the impact of drivers, restraints, and macro indicators on the GCC
and regional AI-based clinical trials solution provider market over the short
term as well as long term. The report is a comprehensive presentation of
trends, forecasts, and dollar values of the GCC AI-based clinical trials solution
provider market. According to the report, the GCC AI-based clinical trials
solution provider market is projected to grow at a significant CAGR over the
forecast period of 2022-2028.
Market
Insight
Artificial intelligence (AI) has
propelled many industries toward a new, highly functional, and powerful state.
Now they are starting to make their way into the clinical research realm
advancing clinical operations, as well as data management. Clinical trials are
a crucial requirement, enabling both innovators and regulators to assess the
efficacy of a candidate drug and establish whether it is safe for use in
humans. It is estimated that nearly 50% of the total time and capital
expenditure during the drug development process, is on conducting clinical
research. Artificial intelligence has the potential to shorten clinical trial
cycle durations while also enhancing productivity and clinical development
outcomes. However, AI adoption in the actual clinical trial process is still in
its early stages.
The Covid-19 pandemic has
glimmered the adoption of technologies that can improve the efficiency and cost
of the traditional clinical trial process. To keep people healthier and safer
in the future, we will have to become increasingly dependent on quick-moving
and highly effective trials. The sudden outbreak of the Covid-19 pandemic has
initiated an augmentation in the deployment of AI-sourced technologies. Rising
acceptance of scientifically highly developed results, intended for the drug
invention, and improvement along with the scrutiny of enlisted information of
the patients are a few factors, accountable for the rise in the infiltration of
AI-sourced medicine development as well as clinical trial results, throughout
the Covid-19 pandemic.
The rising number of clinical
research and studies, increasing government and private investments in
healthcare infrastructure development, and the introduction of novel AI-based technologies
in the healthcare sector are important factors driving the market revenue
growth. The adoption of AI-based platforms and technologies by pharmaceutical
companies and academia, along with the increasing adoption of artificial
intelligence (AI) are the factors driving the market growth. Due to the
possibility of a defective diagnosis, the market is expected to hinder its
growth in the forecasting years. Technological advancements and innovations in AI-based
clinical trials are providing lucrative opportunities for its market in the
upcoming years.
UAE region to dominate in AI-based
clinical trials solution provider market. The healthcare sector’s imperative to
transform has gained momentum during the pandemic when delivering connected,
integrated, and seamless care to patients, those who are elderly or suffering
from chronic conditions, which led to an urgent need to disrupt and reimagine
legacy systems and care delivery pathways. Abu Dhabi-based G42 Healthcare has
invested in a genomic sequencing program to support improved and early
diagnosis of markers for cancer and other chronic conditions, and in the future
to support longevity programs.
Segment
Covered
The report on GCC AI-based clinical
trials solution provider market covers segments such as the clinical trial phase and therapeutic application. On the basis of the clinical trial phase, the
sub-markets include phase -I, phase II, and phase III. On the basis of
therapeutic application, the sub-markets include cancer, cardiovascular
disease, neurological disease, metabolic disease, infectious disease, and
others.
Companies
Profiled:
The report provides profiles of
the companies in the market such as Unlearn AI Inc, Saama Technologies, Inc,
Deep 6 AI, Innoplexus, Symphony AI, Mendel.ai, AiCure, and Ardigen, BioSymetrics,
and GNS Healthcare.
Report
Highlights:
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of the GCC AI-based clinical trials solution provider market. Moreover, the
study highlights current market trends and provides forecasts for 2022-2028. We
also have highlighted future trends in the market that will affect the demand
during the forecast period. Moreover, the competitive analysis given in each
regional market brings an insight into the market share of the leading players.
Please Choose One of them.